Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis

Saltissi, David; Morgan, C.; Rigby, Russell J.; Westhuyzen, Justin

doi:10.1053/ajkd.2002.30547

Cited by 77 publications

(42 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is no evidence to support routine serial monitoring of creatinine kinase and alanine aminotransferase in patients with chronic kidney disease who are receiving low-to moderate-dose statin therapy. [26][27][28] Lifestyle management This section of the guidelines stress the importance of lifestyle management in the care for patients with impaired renal function. Because chronic kidney disease shares common risk factors with cardiovascular disease and diabetes, lifestyle modifications directed at smoking, obesity, alcohol consumption, exercise and diet are important (Box 4).…”

Section: Patients With Large-vessel Renal Vascular Diseasementioning

confidence: 99%

Guidelines for the management of chronic kidney disease

Levin¹,

Hemmelgarn²,

Culleton³

et al. 2008

Canadian Medical Association Journal

306

250

View full text Add to dashboard Cite

Key points• Chronic kidney disease is common and is associated with increased cardiovascular risk.• Attention to cardiovascular risk factors remains the cornerstone of care to delay progression of chronic kidney disease and prevent cardiovascular events.• Randomized clinical trials are lacking; thus, recommendations in the guidelines are based on a synthesis of the best available evidence.• Shared care of patients with chronic kidney disease by general practitioners and specialists is encouraged.

show abstract

Section: Patients With Large-vessel Renal Vascular Diseasementioning

confidence: 99%

Guidelines for the management of chronic kidney disease

Levin¹,

Hemmelgarn²,

Culleton³

et al. 2008

Canadian Medical Association Journal

306

250

View full text Add to dashboard Cite

show abstract

“…It has been shown that HMGRIs effectively reduce the LDL cholesterol concentrations in patients undergoing chronic hemodialysis treatment [20][21][22][23]. This is also true for atorvastatin which has been shown to lower LDL cholesterol and triglyceride levels in patients with diabetic dyslipidemia [24,25] and in those on dialysis [22].…”

Section: Introductionmentioning

confidence: 99%

Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics

Wanner

Krane

März³

et al. 2004

Kidney Blood Press Res

140

View full text Add to dashboard Cite

Patients with type 2 diabetes on dialysis are at a substantially increased risk of cardiovascular and cerebrovascular diseases. Dyslipidemia characterized by moderately elevated low-density lipoprotein cholesterol and high triglycerides and low high-density lipoprotein cholesterol levels is common in this population. We hypothesized that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors would reduce vascular morbidity and mortality in this patient group. The ‘Deutsche Diabetes Dialyse Studie’ (4D study) is a prospective, randomized, double-blind study involving 178 dialysis centers throughout Germany. Between March 1998 and October 2002, 1,255 patients were randomized to either atorvastatin 20 mg or placebo; 677 men and 578 women, aged 30–83 years, have been enrolled. The study will be terminated as soon as the predefined number of 424 patients with primary combined end points (i.e., cardiovascular death, nonfatal myocardial infarction, or fatal/nonfatal stroke) will have occurred. The total cohort had the following characteristics at baseline: the mean age was 65.7 years, 54% were men, 89% had a history of hypertension, 21% had coronary artery disease, 17.8% had a history of stroke or a transient ischemic attack, and 45% suffered from peripheral arterial disease. The mean time interval between the diagnosis of diabetes and the onset of dialysis was 17.4 years. On average, the patients were on hemodialysis for 8.3 months. Mean lipid and lipoprotein levels were: total cholesterol 219 ± 43 mg/dl, low-density lipoprotein cholesterol 126 ± 30 mg/dl, high-density lipoprotein cholesterol 36 ± 13 mg/dl, and triglycerides 264 ± 167 mg/dl. The results of the study will provide important information on the efficacy and safety of atorvastatin to support its use in patients with an impaired renal function who are at a high risk of vascular morbidity and mortality.

show abstract

“…CKD with significant proteinuria is commonly associated with substantial alteration of serum lipid levels. The most common changes being lowered high density lipoprotein cholesterol (HDL-C) levels and elevated level of triglycerides (TG) 3 ; hypercholesterolemia per se might be present in around 50% of patients on dialysis 7 . Among lipid lowering drugs, statins are the most effective in improving the lipid profile and cardiovascular (CV) outcomes in patients with CKD [5][6][7][8][9][10] .…”

Section: I a L D I S T R I B U T I O N U N A U T H O R I Z E D U S mentioning

confidence: 99%

Statins in patients with chronic kidney disease – an attempt at recommendations

Banach

2013

Current Medical Research and Opinion

View full text Add to dashboard Cite

Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis

Cited by 77 publications

References 29 publications

Guidelines for the management of chronic kidney disease

Guidelines for the management of chronic kidney disease

Randomized Controlled Trial on the Efficacy and Safety of Atorvastatin in Patients with Type 2 Diabetes on Hemodialysis (4D Study): Demographic and Baseline Characteristics

Statins in patients with chronic kidney disease – an attempt at recommendations

Contact Info

Product

Resources

About